TWI895384B - 用於治療疾病之法尼醇x受體促效劑 - Google Patents

用於治療疾病之法尼醇x受體促效劑

Info

Publication number
TWI895384B
TWI895384B TW110109622A TW110109622A TWI895384B TW I895384 B TWI895384 B TW I895384B TW 110109622 A TW110109622 A TW 110109622A TW 110109622 A TW110109622 A TW 110109622A TW I895384 B TWI895384 B TW I895384B
Authority
TW
Taiwan
Prior art keywords
disease
compound
liver
administered
fxr
Prior art date
Application number
TW110109622A
Other languages
English (en)
Chinese (zh)
Other versions
TW202143961A (zh
Inventor
肯尼斯 宋
胡伯特 陳
白蘭地 瓦格納
尼可拉斯 Ｄ 史密斯
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202143961A publication Critical patent/TW202143961A/zh
Application granted granted Critical
Publication of TWI895384B publication Critical patent/TWI895384B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110109622A 2020-03-18 2021-03-17 用於治療疾病之法尼醇x受體促效劑 TWI895384B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062991292P 2020-03-18 2020-03-18
US62/991,292 2020-03-18
US202063069667P 2020-08-24 2020-08-24
US63/069,667 2020-08-24
US202163140735P 2021-01-22 2021-01-22
US63/140,735 2021-01-22

Publications (2)

Publication Number Publication Date
TW202143961A TW202143961A (zh) 2021-12-01
TWI895384B true TWI895384B (zh) 2025-09-01

Family

ID=77771857

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110109622A TWI895384B (zh) 2020-03-18 2021-03-17 用於治療疾病之法尼醇x受體促效劑

Country Status (12)

Country Link
US (1) US20230131804A1 (enExample)
EP (1) EP4121048A4 (enExample)
JP (1) JP7851856B2 (enExample)
KR (1) KR20220154801A (enExample)
CN (4) CN120732855A (enExample)
AU (1) AU2021240001A1 (enExample)
BR (1) BR112022018651A2 (enExample)
CA (1) CA3172205A1 (enExample)
IL (1) IL296539A (enExample)
MX (1) MX2022011579A (enExample)
TW (1) TWI895384B (enExample)
WO (1) WO2021188688A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852748B1 (en) 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof
CN120227340A (zh) 2020-03-18 2025-07-01 伊莱利利公司 法尼醇x受体激动剂的制剂
JP7664278B2 (ja) * 2020-03-18 2025-04-17 オルガノボ，インク． ファルネソイドｘ受容体アゴニストの結晶質形態
CN117018000B (zh) * 2023-08-29 2025-01-28 东莞市东南部中心医院(东莞市东南部中医医疗服务中心) 4-胆甾烯-3-酮在制备预防或治疗炎症性肠病药物中的应用
WO2026149323A1 (en) * 2025-01-07 2026-07-16 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of using mitochondrial uncouplers and glp-1 receptor agonists
CN120837611B (zh) * 2025-09-22 2025-12-16 吉林大学 一种经鼻给药的司美格鲁肽制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110637015A (zh) * 2017-03-15 2019-12-31 梅塔科林公司 法尼醇x受体激动剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2016233579A1 (en) * 2015-03-13 2017-10-12 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors
WO2017049176A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3350165B1 (en) 2015-09-16 2023-07-26 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
DK3596053T3 (da) * 2017-03-15 2023-09-25 Organovo Inc Farnesoid-x-receptoragonister og anvendelser deraf
EP3852748B1 (en) * 2018-09-18 2025-09-03 Eli Lilly and Company Farnesoid x receptor agonists and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110637015A (zh) * 2017-03-15 2019-12-31 梅塔科林公司 法尼醇x受体激动剂及其用途

Also Published As

Publication number Publication date
IL296539A (en) 2022-11-01
CN120732854A (zh) 2025-10-03
EP4121048A4 (en) 2024-06-12
US20230131804A1 (en) 2023-04-27
EP4121048A1 (en) 2023-01-25
JP7851856B2 (ja) 2026-04-27
CA3172205A1 (en) 2021-09-23
JP2023518397A (ja) 2023-05-01
KR20220154801A (ko) 2022-11-22
BR112022018651A2 (pt) 2022-11-29
AU2021240001A1 (en) 2022-10-13
CN115666559A (zh) 2023-01-31
WO2021188688A1 (en) 2021-09-23
CN120732855A (zh) 2025-10-03
CN120732856A (zh) 2025-10-03
TW202143961A (zh) 2021-12-01
MX2022011579A (es) 2022-11-30

Similar Documents

Publication Publication Date Title
US20220323414A1 (en) Farnesoid x receptor agonists for the treatment of disease
US20230131804A1 (en) Farnesoid x receptor agonists for the treatment of disease
JP7369033B2 (ja) 線維症の治療
US20170173060A1 (en) Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
CN108289881A (zh) 用于治疗纤维化的赛尼克韦罗联合疗法
EP2943213A1 (en) Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
KR20210092754A (ko) Nafld 및 nash의 병용 치료
KR20170049606A (ko) 간 질환을 치료하기 위한 오메가-3 지방산과 sglt-2 억제제의 조합
TW202114672A (zh) 使用fxr促效劑的肝臟疾病之組合治療
US20190175619A1 (en) Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
TW202143958A (zh) 用於治療疾病之法尼醇x(farnesoid x)受體促效劑
HK40131843A (en) Farnesoid x receptor agonists for the treatment of diseases
HK40131844A (en) Farnesoid x receptor agonists for the treatment of disease
Maroni¹ et al. The pathophysiology of gut-liver
US20250332176A1 (en) Treatment for fibrosis and inhibition of fibrosis
US20220362263A1 (en) Treatment for fibrosis and inhibition of fibrosis
US20220347190A1 (en) Treatment comprising fxr agonists
HK40128498A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK40127982A (en) Methods of using a gip/glp1 co-agonist for therapy
HK40128497A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK1237676A1 (en) Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
HK1197541A (en) Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d